Heterogeneity of viral IL-6 expression in HHV-8-associated diseases.
about
Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signalingBlockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirusMolecular virology of Kaposi's sarcoma-associated herpesvirusK13 blocks KSHV lytic replication and deregulates vIL6 and hIL6 expression: a model of lytic replication induced clonal selection in viral oncogenesis.Early and sustained expression of latent and host modulating genes in coordinated transcriptional program of KSHV productive primary infection of human primary endothelial cells.High-level variability in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populationsGammaherpesviruses and "Hit-and-Run" oncogenesis.Transcription activation of polyadenylated nuclear rna by rta in human herpesvirus 8/Kaposi's sarcoma-associated herpesvirus.Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effectsHow do viruses trick B cells into becoming lymphomas?Evolutionary aspects of oncogenic herpesvirusesPatterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma-associated herpesvirusCharacterization of interactions between RTA and the promoter of polyadenylated nuclear RNA in Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8.Host pathogen interaction and the development of oral lesions.Immune evasion by Kaposi's sarcoma-associated herpesvirus.Transcriptional regulation of the interleukin-6 gene of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus).Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.The KSHV viral interleukin-6 is not essential for latency or lytic replication in BJAB cells.Kaposi's sarcoma-associated herpesvirus infection of endothelial cells inhibits neutrophil recruitment through an interleukin-6-dependent mechanism: a new paradigm for viral immune evasionThe latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3betaHigh-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.HIV-associated multicentric Castleman diseaseViral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies.Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers.The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care.Rhesus macaque rhadinovirus-associated non-Hodgkin lymphoma: animal model for KSHV-associated malignancies.Intracellular signaling mechanisms and activities of human herpesvirus 8 interleukin-6Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines.Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in bloodTargeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.NF-κB as a target for oncogenic viruses.Lytic replication-defective Kaposi's sarcoma-associated herpesvirus: potential role in infection and malignant transformationHHV-8-positive and EBV-positive intravascular lymphoma: an unusual presentation of extracavitary primary effusion lymphoma.Prospects of a novel vaccination strategy for human gamma-herpesviruses.Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patientsAKTivation of PI3K/AKT/mTOR signaling pathway by KSHV.Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.A new primary effusion lymphoma-derived cell line yields a highly infectious Kaposi's sarcoma herpesvirus-containing supernatantKaposi's sarcoma-associated herpesvirus can productively infect primary human keratinocytes and alter their growth properties.Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus
P2860
Q24290902-0BDEDCC8-56DC-4456-93DD-29A9C487B71AQ27486045-D1BB2744-2EB2-402F-BC44-38FEBB06339EQ28363323-F505BF41-B3C0-4D2A-AF8A-F819703A1FABQ33303677-35BCB96D-1DAE-4FFB-B800-04A23AE5DD60Q33623056-3EF35416-2537-44B3-83F1-3FCFD40E8185Q33647633-1E75CD17-9037-4F45-BAAA-9CB0073D68C0Q33810034-324ADF8C-39A8-4B15-80AC-10CE8E936894Q33837983-BBC00C9E-CF99-453E-98B1-49F8982F0DF7Q33849065-306FC028-FE3C-44B5-AD2E-AD9776C8E769Q34020096-2740E0AF-E1C3-465A-ABAC-503748C83B83Q34089478-16A99A01-B5D7-45F0-89DE-C83C98A65E79Q34333321-2BD1BF1A-5467-42A4-8EA6-D3419CD79F33Q34338900-8139E2B8-BF06-48E4-9CAB-12A575E318FFQ34775211-4C8F86CC-B939-40D2-823F-7098A9743C55Q34795543-BEC88F8D-C653-44A3-97B5-C4092D384084Q35000927-854E983D-D803-4931-B857-FCD161025FB7Q35026060-EB741190-0122-4938-8433-48774A31E8B2Q35071118-E3D1542B-C6AA-4B16-AB46-A53397CBBAF7Q35077642-7EF16E40-75F0-4962-BADD-8F690409BB21Q35104781-B32DDE3D-4AD6-4826-8B90-C72026E22808Q35127955-8553A55E-91A9-4BA8-BC16-07FD675001A7Q35226470-00838F58-B514-43FA-A032-1EF723ABC4ACQ35550033-D344E134-B65E-4A8B-B2FF-9234EBABE6ACQ35895560-E4BBC11D-C77B-4443-AA50-804580FC1E9AQ36085023-78B87074-8C41-4185-AFA7-227454929669Q36969847-3EB8E622-F70A-4B30-8F34-165C8EAA70D3Q37033410-05C114D9-225D-496E-8A82-EE97DB019431Q37088015-3967F064-716F-4737-93AB-279665A5029EQ37198986-F821FCA9-186A-4208-93A1-D245D87079C0Q37235682-A16EF027-0BA2-4B7F-B584-A9107401B9A5Q37374081-93FB67E2-7376-4F61-9DD9-6B5377E6E377Q37568044-B3C14802-80E9-4669-8B30-91CEB6D53ADEQ37603069-FE69B550-2200-4810-84DC-EC96711F00E3Q37780705-9F61E717-0FFA-43E6-AA64-8735EE85E018Q37865141-E3C87A67-EE15-4811-94AB-33110BE96FE9Q38073761-5592ABDB-FD09-4CEF-8BA6-25E9B2C42354Q39494864-303CB6B2-1177-490F-AAF6-7A2963D74FA7Q39539612-F4C1BCC9-27AC-4FC7-A717-6616053FFB8CQ39605725-C77FE5A9-C88E-4E0E-B380-BDDFD39B1A72Q39729318-8D64FF65-29BE-449E-B1F3-AFC5478512C7
P2860
Heterogeneity of viral IL-6 expression in HHV-8-associated diseases.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Heterogeneity of viral IL-6 expression in HHV-8-associated diseases.
@ast
Heterogeneity of viral IL-6 expression in HHV-8-associated diseases.
@en
type
label
Heterogeneity of viral IL-6 expression in HHV-8-associated diseases.
@ast
Heterogeneity of viral IL-6 expression in HHV-8-associated diseases.
@en
prefLabel
Heterogeneity of viral IL-6 expression in HHV-8-associated diseases.
@ast
Heterogeneity of viral IL-6 expression in HHV-8-associated diseases.
@en
P2093
P356
P1476
Heterogeneity of viral IL-6 expression in HHV-8-associated diseases.
@en
P2093
Ambinder RF
Browning PJ
Cesarman E
DiGiuseppe JA
Hayward GS
Nicholas J
Orenstein JM
P304
P356
10.1086/314956
P407
P577
1999-09-01T00:00:00Z